Ranbaxy's Patent Litigations in the United States
|
|
ICMR HOME | Case Studies Collection
Case Details:
Case Code : ECON015
Case Length : 14 Pages
Period : 1993-2005
Pub Date : 2006
Teaching Note :Not Available
Organization : Ranbaxy Laboratories Limited
Industry : Pharmaceutical
Countries : USA
To download Ranbaxy's Patent Litigations in the United States case study (Case Code:
ECON015) click on the button below, and select the case from the list of available cases:
Price:
For delivery in electronic format: Rs. 300;
For delivery through courier (within India): Rs. 300 + Shipping & Handling Charges extra
» Economics
Case Studies
» Case Studies Collection
» ICMR HOME
» Short Cases Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Area Specific Case Studies
» Industry Wise Case Studies
» Company Wise Case Studies 
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
Chat with us
Please leave your feedback
|
|
<< Previous
Excerpts
The US Pharmaceutical Industry
|
The US was the largest pharmaceutical market in the
world. In 2004, it alone accounted for $248 billion out of total global
sales of $550 billion.
The US pharmaceutical market was driven by research-based companies such
as Pfizer, GlaxoSmithKline, Sanofi-Aventis, Johnson & Johnson, Merck,
AstraZeneca, Novartis, Bristol-Myers Squibb, Wyeth and Abbott Labs.
Together, these top ten global pharmaceutical giants grossed $235
billion in global sales in 2004 (Refer Exhibit IV and V for global sales
and US sales respectively of the top ten pharmaceutical companies in
2004)... |
|
Product Launches and Patent Litigations
Between 1995 and 1996, Ranbaxy filed two ANDAs. In the subsequent two years, the
number of applications increased to four and then to 14 per year. Ranbaxy
realized that to gain a substantial share of the US generics market, it was
necessary to pursue aggressively 'first-to-file' Para IV ANDAs. It increased its
ANDA filings and rapidly expanded it product portfolio, especially of
antibiotics, in the US...
|
|
Outlook
The large pharmaceuticals companies were keen to protect their patents
with all their might. In 2005, a drug like Lipitor earned nearly $36
million a day for Pfizer (Refer Exhibit VI for the sales of top ten
drugs in the US in 2004).
There were many other drugs that earned anywhere between $3 and $5
million a day for their companies. With such high stakes, it had become
very important for patent-holding companies to fight the generic
challenges... |
Exhibits
Exhibit I: Financial Highlights of Ranbaxy
Exhibit II: The Indian Patent Act of 1970 and the Drug Price Control Order
Exhibit III: Top Ten Pharmaceutical Companies in India in 2004
Exhibit IV: Global Sales and R&D Investment of Top Ten Pharmaceutical Companies
in 2004
Exhibit V: Top Ten Pharmaceutical Companies by U.S. Sales in 2004
Exhibit VI: Top Ten Drugs by U.S. Sales in 2004
Exhibit Vii: Big Pharma's Response to the Challenge of Generics
|
|
